NeoGenomics, Inc.: NeoGenomics Announces RaDaR Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced

Related Keywords

United Kingdom ,Fort Myers ,Florida ,United States ,Georgia ,Tampa ,North Carolina ,Texas ,Research Triangle Park ,Atlanta ,California ,San Diego ,Tennessee ,Singapore ,Houston ,Aliso Viejo ,Cambridge ,Cambridgeshire ,Switzerland ,Charlie Eidson ,Clive Morris ,Mark Mallon ,Karen Chandler Smith ,Inivata Invision ,Doug Brown ,Cancer Research United Kingdom Cambridge Institute ,Neogenomics Inc ,Inivata Limited ,Company Pharma Services Division ,Nasdaq ,University Of Cambridge ,While The Company ,Company Annual Report On Form ,Corporate Development ,Consilium Strategic Communications ,European In Vitro Diagnostics Directive ,Neogenomics Laboratories ,Pharma Services Division ,Privacy Practices ,Breakthrough Device Designation ,Private Securities Litigation Reform Act ,Annual Report ,Corporate Development Officer ,Investor Relations ,Media Contacts ,Neogenomics ,Nnounces ,Radar ,Essay ,Eceives ,Park ,Ubmitted ,Reimbursement ,Oldx ,Program ,